FDA cited 25 telehealth GLP-1 sellers in a single June 2026 enforcement wave

The June 16 batch is part of a wider posting under the FDA's Center for Drug Evaluation and Research. The telehealth-tagged letters carry the subject line "False & Misleading Claims/Misbranded (Telehealth)." All of them are dated June 8. All are signed by Matthew J. Lash, JD, acting director of CDER's Office of Compounding Quality and Compliance. All were triggered by an FDA review of the recipient's website in May 2026.

Each company has fifteen business days from receipt of the letter to respond to FDA's compounding compliance inbox, identify the entities that actually produce the compounded drugs on their site, submit representative labeling, and either remove or modify the cited claims. Each letter ends with the same warning: failure to adequately address the violations may result in "legal action without further notice, including, without limitation, seizure and injunction."

The trade outlet Endpoints News reported on June 17 that FDA had issued warning letters to 25 telehealth companies. That figure is correct, and we have since confirmed it directly: the June 16 posting contains 25 letters carrying the telehealth subject line, all dated June 8. The posting also includes one non-telehealth letter, to Sante Manufacturing Inc., bringing the total to 26.

The legal hook in every letter is the same. Under section 502(a) of the Federal Food, Drug, and Cosmetic Act, a drug is misbranded if its labeling is false or misleading in any particular. Under section 502(bb) — added by the Drug Quality and Security Act in 2013 — a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular. Selling a misbranded drug across state lines violates section 301(a). That's the framework. Inside it, the agency grouped the cited problems into four patterns.

Pattern A — language that implies FDA approval or evaluation. Maximus's website carried the phrases "Clinically studied ingredients," "Clinically studied to help patients…," and "Proven to lose weight effectively." altRx had "GLP-1s are clinically proven medications…" and "…clinically proven weight loss." FDA's objection in both letters is the same sentence: "Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."

Pattern B — describing the source pharmacy as "FDA-approved" or "FDA-licensed." Maximus's site said the compound was sourced from "FDA approved pharmacies." Ready Med's said the compound was sourced from an "FDA licensed compounding facility." The letters quote each phrase, then state plainly: "Compounding facilities, including pharmacies and outsourcing facilities, are not 'FDA-approved' or 'FDA-licensed' entities. The FD&C Act does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities."

This pattern matters more than it sounds. A 503B outsourcing facility can register with the FDA, which is sometimes shorthanded on marketing pages as "FDA approval." Registration is not approval. The FDA inspects registered 503B facilities; it does not approve them or their products. The Q&A page FDA cited in each letter spells this out: compounded drugs "are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing."

Pattern C — describing the compound as the same as a branded drug. Ready Med's site said its compounded products contain "the same active ingredient in Mounjaro® and Zepbound™" and "the same active ingredient in Ozempic® and Rybelsus®." FDA's read of those statements is that they represent the compounded products as having been "FDA-approved or otherwise evaluated for safety and effectiveness when they have not." The technical pharmacology may be true — a properly sourced compounded semaglutide is the same active molecule as Wegovy. The regulatory and quality apparatus around the molecule is not the same, and the FDA's position is that the brand-equivalence framing collapses that distinction in a way that misleads.

Pattern D — putting the telehealth brand's name on the vial. This is the most common cited pattern in the batch, and the most visually concrete. Ready Med's site displayed compounded products labeled "Ready Med" or "Ready Med Medical Weight Loss Center." altRx's site showed vials labeled "altRx." Mint Med's site showed vials labeled "Mint Med." Ezra's site showed vials labeled "Ezra." In each case, FDA's footnote cites 21 C.F.R. § 201.1(h)(2), which reads: "The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded… if the person is not the manufacturer of the product." The telehealth brand is not the compounder. The label, by displaying the brand without qualification, said otherwise.

All 25 letters in the June 16 posting carry the same subject line — "False & Misleading Claims/Misbranded (Telehealth)" — and the same June 8 issue date. In the order FDA's portal lists them:

MARCS-CMS reference numbers for the five letters we read in full are in the references below: Maximus 730095, altRx 728236, Mint Med 730390, Ezra 730995, Ready Med 730317.

This is the slice of the batch FDA itself flags as telehealth-related. Each company sells some version of a cash-pay weight-loss program built around a compounded GLP-1 prescription. The June 16 posting also includes a separate warning letter to Sante Manufacturing Inc., dated June 5, that is not a telehealth letter; it cites current-good-manufacturing-practice violations at a finished-pharmaceutical facility. Different track.

Of the companies named, Maximus is the only one already in our provider review set. The phrases the FDA letter quotes from Maximus's site — "Clinically studied ingredients," "Proven to lose weight effectively," and the reference to "FDA approved pharmacies" — are the kind of marketing language our review's source-hierarchy framework already discounts as company-self-reported. We will publish a dated addendum to the Maximus review noting the warning letter, and re-check the live site after Maximus's fifteen-business-day response window.

On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which is the list of bulk drug substances that outsourcing facilities are allowed to compound from. The agency's stated reason was that it "did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances." Commissioner Marty Makary's quote in the release: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."

The public-comment window on that proposal closes June 29, 2026. After that, the agency will read the docket, weigh comments — most notably the Outsourcing Facilities Association's, given OFA's pending litigation against FDA in the Northern District of Texas — and issue a final determination. The final determination is the step that would actually change the law. There is no public timeline for it; comparable bulks-list rulemakings have run several months to over a year past the comment close.

What's worth getting right about scope: the bulks list proposal applies to 503B outsourcing facilities and to bulk drug substance. It does not, on its face, restrict 503A patient-specific compounding by a state-licensed pharmacy from an ingredient that's a component of an FDA-approved drug. The 503A pathway is narrower and more clinician-driven; it is also the pathway most often invoked when a patient genuinely cannot use a commercial product. The 503B pathway is what the high-volume telehealth supply chain has mostly relied on.

A few things stay the same in the near term. The June 8 warning letters do not suspend the named companies, freeze prescriptions, or remove product from patient supply. They demand a response, a corrective-action plan, and a stop to the cited marketing claims. The fifteen-business-day window from June 8 puts the response deadline at the end of June. If a company doesn't address the violations, the letter says the next step can be seizure or injunction — not, by itself, a recall of patient supply.

A few things are likely to shift. Provider sites will edit copy. Phrases like "FDA-approved pharmacy," "clinically proven," "same as Ozempic," and own-brand vial photography are the obvious targets; expect them to disappear or to be re-worded with qualifications. The 503B bulks list proposal, if finalized after the June 29 comment close, would narrow the supply side of the compounded channel for these molecules. Timing for that is open.

A few things are now clearly different than they were even a year ago. The FDA-approved alternatives have scaled. Novo Nordisk's Wegovy pill — the same active ingredient as Wegovy injection — passed three million U.S. prescriptions in its first five months, per the company's June 7, 2026 release. Eli Lilly's Foundayo (orforglipron), a small-molecule oral GLP-1 approved April 1 and launched April 9, is ramping more slowly but is now covered by major pharmacy benefit managers, including CVS Caremark. When the FDA writes "FDA-approved drugs are available," that's what the agency is pointing at.

What to ask a provider, if any of this affects you: which entity actually compounds the product they ship, and under which legal pathway — 503A patient-specific compounding, or 503B-outsourcing-facility bulk compounding under the shortage exemption that has now ended. If a provider's answer to the first question is themselves, or to the second is some form of "FDA-approved pharmacy," that is the language FDA just said is misleading. That doesn't make the underlying medication unsafe in every case. It does make it harder to evaluate what you're getting.